Pacific Biosciences of California is back in focus after an updated fair value estimate of $2.58 is being weighed against a fresh Street price target of $1.50. That gap reflects a debate you should ...
PACB's strong Q4 results, expanding sequencing tech portfolio and rising system adoption highlight growth momentum despite ...
MENLO PARK, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced its entry into the ...
(RTTNews) - PacBio (PACB), a developer of highly accurate sequencing solutions, is slated to participate in several upcoming investor conferences this month, underscoring its visibility within the ...
Zacks Investment Research on MSN
PacBio wins Basecamp Research deal for Trillion Gene Atlas initiative
Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, recently announced that Basecamp Research has selected its HiFi sequencing technology on the Revio system to support the ...
Gross margin, operating expenses, net loss, and net loss per share are reported on a GAAP and non-GAAP basis. The non-GAAP measures are described below and reconciled to the corresponding GAAP ...
PacBio reports that through its partnership with China-headquartered Berry Genomics, the Sequel II CNDx system has received Class III Medical Device Registration approval from the National Medical ...
Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, has been gaining from its continued product development. The optimism, led by strong third-quarter results, is expected to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results